NOV
35
3
HUM
28
-7
HBI
40
3
PLD
43
3
DG
33
4
MLM
60
3
CME
48
2
CVX
38
6
AZO
55
2
SNA
39
-9
WAT
49
11
CMCSA
49
4
UNP
39
4
HAL
48
5
PM
66
4
CB
51
3
GIS
46
5
AMG
44
-5
DLTR
54
11
HP
34
5
NOV
35
3
HUM
28
-7
HBI
40
3
PLD
43
3
DG
33
4
MLM
60
3
CME
48
2
CVX
38
6
AZO
55
2
SNA
39
-9
WAT
49
11
CMCSA
49
4
UNP
39
4
HAL
48
5
PM
66
4
CB
51
3
GIS
46
5
AMG
44
-5
DLTR
54
11
HP
34
5
Financhill
Back

Sarepta Therapeutics 10K Form

Buy
57

SRPT
Sarepta Therapeutics

Last Price:
$53.80
Seasonality Move:
13.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $1.9B
Cash Flow: $54M
Price / Cash Flow: 0
Annual Sales: $15.77
Price / Book: 3.42

Profitability

EPS (TTM): 2.28000
Net Income (TTM): $235.2M
Gross Margin: $1.6B
Return on Equity: 20.83%
Return on Assets: 6.73%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for SRPT is 83.22%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 29.33% of Gross Profit Margin.
  • The Research & Development expenses have been 42.30% of Revenue.
  • The Interest Expense is 7.82% of Operating Income.
  • The Net Earning history of SRPT is 12.37% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 15 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 0.74
Current Ratio: 4.2
Quick Ratio: 2.74

Price-to-Earnings

Trailing P/E Ratio: 22.99
Forward P/E Ratio: 3.77

SRPT Technical Analysis vs Fundamental Analysis

Buy
57
Sarepta Therapeutics (SRPT) is a Buy

Is Sarepta Therapeutics a Buy or a Sell?